ASMB
$28.46+0.95 (+3.45%)
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Recent News
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +586.28% and +300.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences: Q4 Earnings Snapshot
ASMB) on Thursday reported fourth-quarter net income of $22.1 million, after reporting a loss in the same period a year earlier. On a per-share basis, the South San Francisco, California-based company said it had profit of $2.48. The biotech drug developer posted revenue of $42.5 million in the period.
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -4.35% and -54.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of +16.13% and -4.66%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +228.57% and +7.57%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?